케이바이오
Financials
Valuation Metrics
케이바이오's Market Cap is ₩256B. At end of 2025 it was ₩312B. Ranked #2159 of 2,436 in KR market (top 89%), #1393 of 1,649 on KOSDAQ (top 84%), #92 of 114 in Consumer Durables & Apparel (top 81%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 25.58B KRW | KR#2,159/2,436 Sec#92/114 |
| Revenue | 82.64B KRW | KR#1,516/2,436 Sec#84/114 |
| Net Income | -2.78B KRW | KR—/2,436 Sec—/114 |
| Total Assets | 119.04B KRW | KR#1,620/2,436 Sec#78/114 |
| Net Assets | 104.47B KRW | KR#1,365/2,436 Sec#64/114 |
| Employees | 33 | KR#2,157/2,436 Sec#105/114 |
| Value | ||
| P/B | 0.24x | KR#210/2,436 Sec#23/114 |
| P/S | 0.31x | KR#620/2,436 Sec#55/114 |
| FCF Yield | 31.90% | KR#177/2,436 Sec#11/114 |
| Profitability | ||
| ROE | -2.66% | KR#1,656/2,436 Sec#83/114 |
| ROA | -2.34% | KR#1,726/2,436 Sec#85/114 |
| Op. Margin | 0.45% | KR#1,553/2,436 Sec#74/114 |
| Revenue Growth | -22.75% | KR#2,099/2,436 Sec#107/114 |
| Earnings Growth | 4713.37% | KR#15/2,436 Sec#2/114 |
| Financial Health | ||
| Debt Ratio | 113.95% | KR#529/2,436 Sec#30/114 |
| FCF | 8.16B KRW | KR#767/2,436 Sec#38/114 |
| Cash | 28.09B KRW | KR#1,045/2,436 Sec#39/114 |
| Current Ratio | 5.84x | KR#235/2,436 Sec#8/114 |
| Net Debt/EBITDA | -75.36x | KR#2/2,436 Sec#1/114 |
| Performance | ||
| 1Y Return | -28.92% | KR#1,539/2,436 Sec#70/114 |
| 1M Return | 20.63% | KR#119/2,436 Sec#8/114 |
| From 52W High | -64.07% | KR#1,907/2,436 Sec#90/114 |
| 1Y MDD | -70.81% | KR#1,984/2,436 Sec#93/114 |
| Trading | ||
| Volume | 194,341 shares | KR#588/2,436 Sec#27/114 |
| Foreign Own. | 4.46% | KR#863/2,436 Sec#31/114 |
| Per Share | ||
| EPS | -101 KRW | KR—/2,436 Sec—/114 |
| BPS | 2,330 KRW | KR#1,954/2,436 Sec#96/114 |
Company Info
K-Bio, established in 1997, expanded its business by acquiring CureBio's distribution division, adding a bio-distribution segment. The company operates two main businesses: distributing life science equipment and reagents, and developing video security equipment and ICT solutions. Leveraging agency contracts with global firms, K-Bio supplies products to universities and hospitals across Seoul and Gyeonggi. The company is actively developing and launching new IoT-based ICT products, including integrated control solutions and GIS MAP systems, from its headquarters in Gangdong-gu, Seoul.